The oral azacitidine/cedazuridine combination was compared with subcutaneous azacitidine in the phase 3 portion of the AZTOUND trial.
|Videos|March 13, 2019
Optimal Treatment of Chemoresistant mCRC
Optimal Treatment of Chemoresistant mCRC
Advertisement
Case: A 60-Year-Old Male With mCRC
Initial presentation
April 2015
- A 60-yearold man was referred to gastroenterology after complaining of general malaise and alternating constipation with bloody diarrhea.
- PE: Showed left-sided lower abdominal pain
- Carcinoembryonic antigen (CEA); 8.1 mg/L
- Colonoscopy revealed a left-sided adenocarcinoma of the colon
- Surgery: left hemicolectomy
- Pathology: well-differentiated adenocarcinoma
- PET/CT: 15/15 lymph nodes tested negative
- Staging: IIIA
- ECOG PS 0
- Patient received adjuvant mFOLFOX4
April 2018
- 24 months later, the patient complained of mild abdominal distension and his stools were pencil-shaped with some presence of blood
- PET/CT scan showed widespread small liver lesions
- CEA; 14.7 mg/L
- Biopsy was CK2-positive
- Molecular testing; allRAS&BRAFWT
- ECOG PS 1
- Patient began treatment with FOLFIRI + bevacizumab
February 2019
- PET/CT scan showed evidence of new liver lesions and a 2-cm mass in the right lung
- CEA; 31.7 mg/L
- Patient started on regorafenib 80 mg/day
Advertisement
Related to this article
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Late 2026 FDA oncology rulings may reshape care—from CSF-1R and ALK drugs to oral SERDs and BCMA CAR T breakthroughs.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Resection with cesium-131 tile-based radiation therapy prolonged time to surgical bed recurrence vs resection with stereotactic radiation in the phase 3 ROADS trial.
Degevma was approved for skeletal-related events in adults with bone metastases, giant cell tumor of bone, and the treatment of hypercalcemia of malignancy.
FDA fast-tracks plinabulin plus docetaxel for post-immunotherapy non-squamous NSCLC, as DUBLIN-4 phase 3 targets survival gains.
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5